Ahmad Anam, Moore Terry
Internal Medicine, St. Luke's Hospital, Chesterfield, USA.
Internal Medicine, Saint Louis University School of Medicine, St. Louis, USA.
Cureus. 2024 Jun 12;16(6):e62247. doi: 10.7759/cureus.62247. eCollection 2024 Jun.
Pyogenic arthritis, acne, pyoderma gangrenosum, and suppurative hidradenitis (PAPASH); pyogenic arthritis, pyoderma gangrenosum (PG), and acne; PG, acne, hidradenitis suppurativa; and PG, acne, spondylarthritis (PASS) are all part of a spectrum of autoinflammatory disorders that share similar pathogenesis. They are related to various mutations in the proline-serine-threonine phosphatase interacting protein 1, leading to dysregulation of the innate immune system and overproduction of interleukin (IL)-1, IL-17, and IL-23 and tumor necrosis factor (TNF)-α. Targeting these cytokines with biologics plays an important role in treatment. Here, we are describing the case of a young male with PAPASH syndrome who was treated with TNF-α and IL-1 inhibitor.
化脓性关节炎、痤疮、坏疽性脓皮病和化脓性汗腺炎(PAPASH);化脓性关节炎、坏疽性脓皮病(PG)和痤疮;PG、痤疮、化脓性汗腺炎;以及PG、痤疮、脊柱关节炎(PASS)均属于一系列具有相似发病机制的自身炎症性疾病。它们与脯氨酸 - 丝氨酸 - 苏氨酸磷酸酶相互作用蛋白1的各种突变有关,导致先天性免疫系统失调以及白细胞介素(IL)-1、IL-17、IL-23和肿瘤坏死因子(TNF)-α过度产生。使用生物制剂靶向这些细胞因子在治疗中起着重要作用。在此,我们描述了一名患有PAPASH综合征的年轻男性患者,该患者接受了TNF-α和IL-1抑制剂治疗的病例。